|
|
Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease |
1.0.0 |
2019-02-27 16:03:03.718424 |
|
|
A role for APP in Wnt signalling links synapse loss with β-amyloid production. |
1.0.0 |
2019-02-27 16:04:37.884290 |
|
|
FK506-Binding Protein 12.6/1b, a Negative Regulator of [Ca2], Rescues Memory and Restores Genomic Regulation in the Hippocampus of Aging Rats |
1.0.0 |
2019-02-27 16:09:39.059616 |
|
|
Identification of a novel aspartic protease (Asp 2) as beta-secretase |
1.0.0 |
2019-02-27 16:11:44.126044 |
|
|
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans |
0.1.0 |
2019-02-27 16:11:44.417394 |
|
|
Estrogen receptor-α is localized to neurofibrillary tangles in Alzheimer's disease |
1.0.0 |
2019-02-27 16:11:57.120251 |
|
|
Amyloid β oligomers (AβOs) in Alzheimer’s disease |
1.0.0 |
2019-02-27 16:11:58.050677 |
|
|
Amyloid Precursor Protein Trafficking, Processing, and Function |
1.0.0 |
2019-02-27 16:11:59.074651 |
|
|
Effects of peptides derived from BACE1 catalytic domain on APP processing |
1.0.0 |
2019-02-27 16:11:59.434046 |
|
|
APP processing in Alzheimer's disease |
1.0.1 |
2019-02-27 16:13:40.534508 |
|
|
Proteolytic processing of Alzeimer's beta-amyloid precursor protein |
1.0.1 |
2019-02-27 16:13:42.416728 |
|
|
albuquerque2009 |
1.0.0 |
2019-02-27 16:13:46.488811 |
|
|
Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. |
1.0.0 |
2019-02-27 16:13:50.629951 |
|
|
The Nicotinic Acetylcholine Receptor: The Founding Father of the Pentameric Ligand-gated Ion Channel Superfamily |
1.0.1 |
2019-02-27 16:13:52.120863 |
|
|
Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. |
1.0.0 |
2019-02-27 16:13:53.676370 |
|
|
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System |
1.0.0 |
2019-02-27 16:16:01.518015 |
|
|
Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine |
1.0.1 |
2019-02-27 16:16:02.903816 |
|
|
The CRF1 receptor antagonist, antalarmin, reverses isolation-induced up-regulation of dopamine D2 receptors in the amygdala and nucleus accumbens of fawn-hooded rats |
1.0.0 |
2019-02-27 16:16:03.579988 |
|
|
Alzheimer's Disease: Targeting the Cholinergic System |
1.0.0 |
2019-02-27 16:16:05.224392 |
|
|
Interplay of neurotransmitters in Alzheimer's disease |
1.0.0 |
2019-02-27 16:16:39.785691 |
|
|
M1 muscarinic acetylcholine receptor in Alzheimer’s disease |
1.0.0 |
2019-02-27 16:16:41.068280 |
|
|
Identification and Characterization of a G Protein-binding Cluster in alpha7 Nicotinic Acetylcholine Receptors |
1.0.0 |
2019-02-27 16:16:42.667314 |
|
|
Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment |
1.0.1 |
2019-02-27 16:16:44.555357 |
|
|
A role for b2* nicotinic receptors in a model of local amyloid pathology induced in dentate gyrus |
1.0.0 |
2019-02-27 16:16:45.569644 |
|
|
Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease |
1.0.0 |
2019-02-27 16:16:45.834326 |
|
|
Nuclear receptors as therapeutic targets for Alzheimer's disease. |
1.0.0 |
2019-02-27 16:16:47.479877 |
|
|
NACHO Mediates Nicotinic Acetylcholine Receptor Function throughout the Brain |
1.0.0 |
2019-02-27 16:16:48.477142 |
|
|
Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses |
1.0.0 |
2019-02-27 16:16:49.928729 |
|
|
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications |
1.0.0 |
2019-02-27 16:20:49.011315 |
|
|
Nicotinic Receptor Abnormalities of Alzheimer’s Disease: Therapeutic Implications |
1.0.0 |
2019-02-27 16:20:50.271424 |
|
|
B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor |
1.0.0 |
2019-02-27 16:20:50.676574 |
|
|
The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice |
1.0.0 |
2019-02-27 16:20:50.917217 |
|
|
Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice |
1.0.0 |
2019-02-27 16:20:51.215175 |
|
|
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system |
1.0.0 |
2019-02-27 16:20:52.613678 |
|
|
Chaperoning α7 neuronal nicotinic acetylcholine receptors |
1.0.0 |
2019-02-27 16:20:53.724010 |
|
|
Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype |
1.0.0 |
2019-02-27 16:20:54.095975 |
|
|
Naturally-expressed nicotinic acetylcholine receptor subtypes |
1.0.0 |
2019-02-27 16:20:54.572895 |
|
|
Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors. |
1.0.0 |
2019-02-27 16:20:55.672615 |
|
|
Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation |
1.0.0 |
2019-02-27 16:20:56.478525 |
|
|
Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine |
1.0.0 |
2019-02-27 16:20:57.172912 |
|
|
A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. |
1.0.0 |
2019-02-27 16:20:57.755792 |
|
|
The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg |
1.0.0 |
2019-02-27 16:21:00.339336 |
|
|
Perilous journey: a tour of the ubiquitin–proteasome system |
1.0.0 |
2019-02-27 16:21:01.751921 |
|
|
The Biology of Proteostasis in Aging and Disease |
1.0.0 |
2019-02-27 16:21:02.954973 |
|
|
A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways |
1.0.0 |
2019-02-27 16:21:26.664755 |
|
|
Alpha-synuclein oligomers: a new hope |
1.0.0 |
2019-02-27 16:21:28.171480 |
|
|
Structural and functional properties of prefibrillar α-synuclein oligomers |
1.0.0 |
2019-02-27 16:21:28.540837 |
|
|
Corticotropin-releasing factor regulates caspase-3 and may protect developing zebrafish from stress-induced apoptosis |
1.0.0 |
2019-02-27 16:21:28.782669 |
|
|
The effect of CRH and its inhibitor, antalarmin, on in vitro growth of preantral mouse follicles, early embryo development, and steroidogenesis. |
1.0.0 |
2019-02-27 16:21:28.991106 |
|
|
In Vivo and In Vitro Characterization of Antalarmin, a Nonpeptide Corticotropin-Releasing Hormone (CRH) Receptor Antagonist: Suppression of Pituitary ACTH Release and Peripheral Inflammation |
1.0.0 |
2019-02-27 16:21:29.186958 |
|
|
Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 |
1.0.0 |
2019-02-27 16:21:29.649562 |
|
|
MMP-9 and MMP-2 Contribute to Neuronal Cell Death in iPSC Models of Frontotemporal Dementia with MAPT Mutations |
1.0.0 |
2019-02-27 16:21:30.615791 |
|
|
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing |
1.0.0 |
2019-02-27 16:21:33.100673 |
|
|
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease |
0.1.0 |
2019-02-27 16:22:58.818193 |
|
|
Interplay of pathogenic forms of human tau with different autophagic pathways |
1.0.1 |
2019-02-27 16:22:59.998765 |
|
|
Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau |
1.0.0 |
2019-02-27 16:23:00.972604 |
|
|
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease |
1.0.0 |
2019-02-27 16:23:03.233941 |
|
|
Analysis of Isoform-specific Tau Aggregates Suggests a Common Toxic Mechanism Involving Similar Pathological Conformations and Axonal Transport Inhibition |
1.0.1 |
2019-02-27 16:23:04.480011 |
|
|
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers |
1.0.0 |
2019-02-27 16:23:05.115212 |
|
|
Adenosine A1 receptor antagonist 64627 alleviates axonopathy caused by human Tau ΔK280 |
1.0.0 |
2019-02-27 16:23:05.784204 |
|
|
Identification of the Tau phosphorylation pattern that drives its aggregation |
1.0.0 |
2019-02-27 16:23:06.189035 |
|
|
Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways |
1.0.1 |
2019-02-27 16:23:06.695264 |
|
|
Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers |
1.0.0 |
2019-02-27 16:23:07.337195 |
|
|
Anti-aggregant tau mutant promotes neurogenesis |
1.0.0 |
2019-02-27 16:23:07.931827 |
|
|
Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. |
1.0.0 |
2019-02-27 16:23:08.341163 |
|
|
Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. |
1.0.0 |
2019-02-27 16:23:08.960689 |
|
|
TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading |
1.0.0 |
2019-02-27 16:23:09.479620 |
|
|
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies |
1.0.0 |
2019-02-27 16:23:10.715799 |
|
|
Tau protein aggregation is associated with cellular senescence in the brain |
1.0.0 |
2019-02-27 16:23:12.384027 |
|
|
Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro |
1.0.0 |
2019-02-27 16:23:13.180624 |
|
|
Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β. |
1.0.0 |
2019-02-27 16:23:13.704454 |
|
|
Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) |
1.0.1 |
2019-02-27 16:23:14.340071 |
|
|
Tau oligomers-Cytotoxicity, propagation, and mitochondrial damage |
1.0.0 |
2019-02-27 16:23:15.578081 |
|
|
Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies |
1.0.0 |
2019-02-27 16:23:17.019021 |
|
|
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies |
1.0.0 |
2019-02-27 16:23:18.639513 |
|
|
Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain |
1.0.1 |
2019-02-27 16:23:19.363126 |
|
|
Clearance systems in the brain-implications for Alzheimer disease. |
1.0.1 |
2019-02-27 16:23:20.254439 |
|
|
Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. |
1.0.0 |
2019-02-27 16:23:20.730252 |
|
|
Tau oligomers and tau toxicity in neurodegenerative disease |
1.0.0 |
2019-02-27 16:23:21.348281 |
|
|
Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:from Mechanisms to Therapy |
1.0.1 |
2019-02-27 16:23:23.109407 |
|
|
Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology |
1.0.0 |
2019-02-27 16:23:23.979842 |
|
|
Tau Biochemistry |
1.2.5 |
2019-02-27 16:23:25.281502 |
|
|
TAU and Interaction Partners |
1.2.5 |
2019-02-27 16:23:28.127661 |
|
|
Tau Effect on Mitochondria |
1.0.3 |
2019-02-27 16:23:29.416538 |
|
|
Tau Modifications |
1.9.5 |
2019-02-27 16:23:43.071783 |
|
|
Inflammasome activation and innate immunity in Alzheimer’s disease |
1.0.2 |
2019-02-27 16:23:47.824260 |
|
|
Activation and regulation of the inflammasomes |
1.0.0 |
2019-02-27 16:23:49.354725 |
|
|
The role of inflammasome in Alzheimer’s disease |
1.0.3 |
2019-02-27 16:23:51.037226 |
|
|
Inflammasome Involvement in Alzheimer’s Disease |
1.0.0 |
2019-02-27 16:23:52.213754 |
|
|
Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer’s Disease |
1.0.0 |
2019-03-15 15:30:52.539195 |
|
|
Anatabine ameliorates experimental autoimmune thyroiditis. |
1.0.0 |
2019-03-15 15:36:29.879540 |
|
|
Anatabine lowers Alzheimer's Aβ production in vitro and in vivo |
1.0.0 |
2019-03-15 15:36:31.067007 |
|
|
Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice |
1.0.0 |
2019-03-15 15:36:31.506059 |
|
|
Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons |
1.0.0 |
2019-03-15 15:36:32.672505 |
|
|
Chronic Anatabine Treatment Reduces Alzheimer ’ s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD |
1.0.0 |
2019-03-15 15:43:43.725047 |
|
|
Silencing of PMT expression caused a surge of anatabine accumulation in tobacco |
1.0.0 |
2019-03-15 15:43:44.033515 |
|
|
Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation |
1.0.0 |
2019-03-15 15:43:46.388953 |
|
|
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer |
1.0.0 |
2019-03-15 15:43:48.204641 |
|
|
Assembly and structure of protein phosphatase 2A |
1.0.0 |
2019-03-15 15:43:49.323481 |
|
|
Protein phosphatase 2A dysfunction in Alzheimer’s disease |
1.0.0 |
2019-03-15 15:43:51.414746 |
|
|
Axonal Transport, Tau Protein, and Neurodegeneration in Alzheimer’s Disease |
1.0.0 |
2019-03-15 15:43:52.503806 |
|
|
PP2A and Alzheimer Disease |
1.0.0 |
2019-03-15 15:43:53.243397 |
|
|
Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo |
1.0.0 |
2019-03-15 15:43:53.904572 |
|
|
Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity |
1.0.0 |
2019-03-15 15:43:54.543682 |
|
|
Alzheimer’s disease and the autophagic-lysosomal system |
1.0.0 |
2019-03-15 15:43:56.560174 |
|
|
The Ubiquitin–Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease |
1.0.0 |
2019-03-15 15:43:59.704155 |
|
|
Molecular Chaperone Functions in Protein Folding and Proteostasis |
1.0.0 |
2019-03-15 15:44:01.488533 |
|
|
Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection |
1.0.0 |
2019-03-15 15:44:03.090518 |
|
|
Molecular chaperones and proteostasis regulation during redox imbalance |
1.0.0 |
2019-03-15 15:44:04.581803 |
|
|
Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition |
1.0.0 |
2019-03-15 15:44:05.117689 |
|
|
Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity |
1.0.0 |
2019-03-15 15:44:06.795659 |
|
|
Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability |
1.0.0 |
2019-03-15 15:44:07.427921 |
|
|
Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation |
1.0.0 |
2019-03-15 15:44:07.833235 |
|
|
Inert and seed-competent tau monomers suggest structural origins of aggregation |
1.0.0 |
2019-03-15 15:44:08.412900 |
|
|
The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation* |
1.0.0 |
2019-03-15 15:44:09.319421 |
|
|
Screening of a neuronal cell model of Tau pathology for therapeutic compounds |
1.0.0 |
2019-03-15 15:44:10.243539 |
|
|
Caenorhabditis elegans models of tauopathy |
1.0.0 |
2019-03-15 15:44:11.534594 |
|
|
Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes |
1.0.0 |
2019-03-15 15:44:12.611191 |
|
|
Alzheimer's disease pathological lesions activate the spleen tyrosine kinase. |
1.0.0 |
2019-03-15 15:44:13.200081 |
|
|
Tau in physiology and pathology |
1.0.0 |
2019-03-15 15:44:15.579027 |
|
|
New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases |
1.0.0 |
2019-05-15 22:26:57.143076 |
|
|
RelB/p50 complexes regulate cytokine-induced YKL-40 expression |
1.0.0 |
2019-05-15 22:26:58.136137 |
|
|
Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. |
1.0.0 |
2019-05-15 22:26:59.186629 |
|
|
Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) - a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease |
1.0.0 |
2019-05-15 22:27:01.025946 |
|
|
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease |
1.0.0 |
2019-05-15 22:27:02.900011 |
|
|
Upstream regulators and downstream effectors of NF-κBinAlzheimer's disease |
1.0.0 |
2019-05-15 22:27:04.841281 |
|
|
Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis |
1.0.0 |
2019-05-15 22:27:06.155648 |
|
|
mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders |
1.0.0 |
2019-05-15 22:27:09.104510 |
|
|
Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome |
1.0.0 |
2019-05-15 22:27:11.835960 |
|
|
The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse |
1.0.0 |
2019-05-15 22:27:12.596666 |
|
|
Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP |
1.0.0 |
2019-05-15 22:27:13.080120 |
|
|
Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice |
1.0.0 |
2019-05-15 22:27:13.402814 |
|
|
Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems |
1.0.1 |
2019-05-15 22:27:15.199141 |
|
|
Heme Curation |
0.0.1-dev |
2019-09-10 13:50:35.331210 |
